Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
@Mr_mike1
1. Avacta
"Avacta shares have dropped from a record 185p in early February to just 104p today, leaving the junior with a £286 million market cap. While it remains highly capitalised with £27 million on the balance sheet, it’s a very strong potential buyout target".
Avacta's record high was actually 285p and not 185p. Think the author needs to do more research.
@Watching2
The levels of Dox in the tumour is “SIGNIFICNT” and, based upon the monitoring of Dox in urine and blood plasma, (non-tumour areas), we have not reached the Maximum Tolerated Dose, (MTD), yet.
The data being gathered in Phase1a is extremely valuable both medically and commercially. Phase1a confirms that the pre|CISION™ platform works. The pre|CISION™ platform can be used with other toxins but these will require their own clinical studies, (licensing deals ££)
Phase1b:
The protocols for Phase1B are being reviewed.
Patients in Phase1b may be dosed at two levels. Some at a level below MTD and some at a higher level or MTD. If MTD proves to be too high, the levels will be dropped to the safer lower level. If MTD is shown to be safe, the patients on the lower level dose may move up to the higher dose, (MTD).
Phase1b is studying efficacy and, for the reason above, MTD is required before proceeding.
At the recent AGM, a member of the audience asked why the Avacta executive team are not investing more of their own money in Avacta shares.
Alistair Smith (AS) commented that he has shares that are visible in the public domain and additional shares in other wrappers such as SIPPS, ISA’s, etc. When pushed, AS commented that his current shareholding exceeds 500K shares. He is also impacted by the current share price.
Eliot Forster, Non-Executive Chairman, is also holding a significant number of shares.
Both Eliot and Alistair were very confident in Avacta’s strategy and growth plans and they both remain committed and invested. Still see Avacta as a £bn company.
Draw your own conclusions from the above. I have mine and remain invested.
GLA
Reply to Twitter comment:
AVA6000 Cohort V (x2.2) completed and currently recruiting for Cohort VI at x2.7. We should expect a Cohort VI first dose RNS soon.
The levels of Dox in the tumour is “SIGNIFICNT” and, based upon the monitoring of Dox in urine and blood plasma, (non-tumour areas), we have not reached the Maximum Tolerated Dose, (MTD), yet.
The data being gathered in Phase1a is extremely valuable both medically and commercially. Phase1a confirms that the pre|CISION™ platform works. The pre|CISION™ platform can be used with other toxins but these will require their own clinical studies.
The fact that Phase1a is confirming that the pre|CISION™ platform works, there may be opportunities for licensing deals (£m) once the phase1a data is published and is generally available to the market. The published data may also make Avacta very attractive M&A to a big pharma.
When will the above happen, certainly with the next 6 months. Possibly sooner.
GLA
@nursesteve
The Avacta team have been travelling and speaking to potential partners about pre|CISION™, AVA6000 and the pre|CISION™ platform with others toxins. Full data on Phase1a (in human) will move these discussions further and completing Phase1b in-house will put Avacta in a very strong commercial position.
Sources:
Alistair Smith video comments (Video - mins - 16:30 to 21:00), off-line discussions over lunch, the AVA6000 afternoon presentation (hours - 13:00 to 13:20) and further off-line discussions after 14:00.
Saturday: going off-line for a few hours. Have another listen to the video (16:30 to 21:00)
I was able to attend the AGM on Wednesday 28th June 2023.
The meeting started at 10:30, was on-line 11:00 to 12:00, but continued until 14:00. We were also able to have off-line discussions with Alistair Smith, the executive team and the front end scientists.
Phase1a:
Cohort V delivered Doxorubicin at x2.2 normal levels. Cohorts VI will commence early July (RNS pending) and deliver Doxorubicin at x2.7 normal levels. There may/may not be a need for Cohort VII with Doxorubicin delivered in volumes >x3 normal levels.
Alistair stated during the on-line video presentation that:
“We are seeing therapeutically significant levels of Dox in the tumour biopsies”. To repeat, as Alistair did, “THERAPUTICALLY SIGNIFICNT LEVELS”.
Alistair goes on to say, “we know the levels of doxorubicin required to make the drug work and the levels we are seeing in the biopsies are greater. That’s what we can say factually now”. Alistair goes on to say, “Why the H*ll wouldn’t it work”?
Watch the AGM video from 1:04:25 – 1:08:50 https://www.youtube.com/watch?v=DlHRRmycxTY
Phase1b:
The protocols for Phase1B are being reviewed.
Patients in Phase1b may be dosed at two levels. Some at a level below MTD and some at a higher level or MTD. If MTD proves to be too high, the levels will be dropped to the safer lower level. If MTD is shown to be safe, the patients on the lower level dose may move up to the higher dose, (MTD).
Phase1b is studying efficacy and, for the reason above, MTD is required before proceeding.
Partnerships & Deals:
The early stage trials were performed in the lab and in mice. The Phase1a trial is in real human patients and the data being gathered is immensely valuable. It demonstrates to Avacta, their partners and the markets that the pre|CISION™ platform and AVA6000 works. The data is extremely valuable in both medical and commercial (£) terms. Some early stage partnership discussions are in place.
Comment:
There has been a great deal posted (500+) and discussed since the AGM. I have delayed this post to ensure that this very important part of the discussion does not get lost amongst the volume of comments.
If you feel the comments above from Alistair Smith and the Avacta team are important, please keep them at the top for all to read and digest.
I remain invested and look forward to the success of Avacta.
As ever, GLA.
PS: There were also some very positive comments during the diagnostics discussions also.
It’s not lack of orders that kills a business, its lack of cash. I do hope we have not reached that stage in the. The AVO proton system is evolutionary and the development work and intellectual property must be worth something to someone, (Varian, Siemens, Elekta, etc?).
We will have to wait and see. GLA
AS was asked why Avacta, with so much to offer, is valued at £300m. As, and the other exec’s, are personally invested and they understand and share the current shareholder frustration(s).
Trinity Delta suggest the share price should be around £ 2.28, (current x2). https://www.trinitydelta.org/research-notes/diagnostics-build-out-continues-with-coris-acquisition/
No definitive answer. Personally, I intend to hold my Avacta investment.
Rather a long day yesterday travelling to and from the Avacta AGM. In my opinion, it was very much worth the effort. Very impressed with the Avacta team and this will be a once in a lifetime opportunity for many.
Finances (£):
Avacta is funded and has tens of £m’s in the bank. There are no plans for a fund raise. Subject to how the multiple projects and partnerships develop, there may never be another fund raise.
Diagnostics:
The global demand for point of care (POC) testing has been growing for years and there are multiple opportunities. Avacta has a diagnostic strategy which required the acquisition of both Launch Diagnostics and Coris. Both of these business are profitable and will expand in to Germany, (largest European market), and the rest of Europe. Both businesses generate cash/profits and these will support the Therapeutics business during this evolutionary period.
pre|CISION™
The AVA6000 Phase 1a trials have shown that the pre|CISION™ platform works. Cohort V used Doxorubicin at x2.2 normal dosage and Cohort VI, currently recruiting and starting soon, will use x2.7. Once we achieve MTD, we move to Phase 1b.
Phase1b study will be in the UK and USA and will offer an initial evaluation of efficacy. Avacta would like to keep this process in-house which will put the group in a much stronger position when it comes to discussing commercial deals.
Precision Revenue Opportunities:
The pre|CISION™ platform works and there are multiple opportunities for revenue through partnerships. AVA6000 will ideally be kept in house, however, there are many pharma’s out there with therapeutic products which are restricted due to toxicities and side effects. These companies can use the pre|CISION™ platform to bring their products to market and, potentially, save many lives. They will also pay Avacta for the use of pre|CISION™.
Avacta Team:
I had the opportunity to discuss the science with several members of the Avacta executive and scientific team yesterday. They fill me with confidence. Each member of the executive team are strongly committed to making the science work and each is invested (£) in the business.
Share Price:
We, as investors, need to ignore the current share price fluctuations. Avacta is a business with unique scientific offerings and strong growth plans. It may take a few months, or years, for Avacta to become a £bn company, however, in my opinion, this is a buy and hold.
Alternatively, with the product portfolio, Avacta could also be a very attractive M&A target for big pharma. An acquisition could happen at any time!
That’s my take on the day.
As ever, GLA
That's the first 2 x RNS and we still have 7 full trading days before the AGM.
Next one's could be:
- Completion of Cohort V
- Start Cohort VI or MTD found
- Date for Phase 1b
- Etc, etc, etc, ......
And we are funded.
GLA
Avacta is funded well in to 2024 and possibly beyond.
“The total gross proceeds raised pursuant to the Fundraise, as announced on 18 October 2022, amount to approximately £64.0 million”.
https://avacta.com/result-of-the-open-offer/
Cohort IV completed January 2023
https://avacta.com/avacta-announces-successful-completion-of-fourth-dose-escalation-in-ava6000-phase-1-clinical-study/
5th & 24th April 2023, Cohort V in the UK and USA.
Doctor William Tap, “If we have a version of Doxorubicin (AVA6000) that works better than the current offering then, overnight, that becomes the new standard of care”, involved in US testing.
https://avacta.com/first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study/
https://avacta.com/first-patient-dosed-in-the-us-in-avactas-ava6000-phase-1-clinical-study/
Results of Cohort V, possible MTD and commencement of Phase 1b pending.
Possible RNS before the AGM.
5th June 2023
Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake
https://avacta.com/avacta-achieves-second-milestone-in-affyxell-joint-venture-triggering-increased-equity-stake/
28th June 2023
Avacta AGM at The Royal Society of Medicine, London.
https://avacta.com/avacta-annual-general-meeting-and-shareholder-event-detailed-agenda/
10:30 Formal AGM Business and Voting on Resolutions.
11:00 Business Update and Q&A: CEO Alastair Smith.
12:00 Lunch and poster session:
• AVA6000 Poster
• AVA3996 Poster
• Affimer Therapeutics Poster
• Affimer Diagnostics Poster
• Launch Diagnostics Stand
13:00 AVA6000 Review of Public Domain Clinical Data.
13:20 Diagnostics Division Strategy with Q&A: Alastair Smith.
13:40 Closing comments and final Q&A: Alastair Smith.
7 full working days until the AGM. Who knows what might land next week?
GLA
The AGM is being held on 28th June 2023 and starts at 10:30. We all have a lot of questions relating to AVA6000 Phase 1a/b, AVA3996, AffyXell, etc.
With two weeks until the AGM, an RNS could occur at any time and could make a significant, positive change to the share price.
Frustrating silence, but lot’s going on at Avacta.
GLA
05 Apr 2023
First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation Study
https://avacta.com/first-patient-dosed-in-fifth-cohort-of-ava6000-phase-ia-dose-escalation-study/
27 Apr 2023
First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study
https://avacta.com/first-patient-dosed-in-the-us-in-avactas-ava6000-phase-1-clinical-study/
AVA6000 Phase 1B for Cancer
This trial will test the safety, effectiveness, and how the body processes a new drug for patients with cancer. It'll use a 3+3 design to find the maximum tolerated dose and recommended phase II dose.
https://www.withpower.com/trial/phase-1-sarcoma-6-2021-6f477
2 months since the start of Cohort V. Do we now have the results and possible MTD?
If we have MTD, Phase 1B could start in the coming weeks.
If Cohort V has found MTD, do we start Phase 1B at Cohort IV levels?
The next chapter in this revolutionary cancer treatment is pending?
An RNS coming from Avacta soon?
GLA
Cycle 1, 21 days
- Maximum-tolerated dose (MTD) or Recommended Phase 2 dose (RP2D)
- Number of participants with dose-limiting toxicities (DLTs)
- Percentage of patients with Adverse Events (AEs) at RP2D AVA6000 dose level in tumour-specific expansion arms.
- Percentage of patients with Dose-Limiting toxicities (DLTs) of AVA6000 during the DLT period
GLA to all Participants & LTH's
June 2-6, 2023 • McCormick Place • Chicago, IL & Online
https://conferences.asco.org/am/attend